TY - JOUR
T1 - Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome
AU - Seeds, Michael C.
AU - Grier, Bonnie L.
AU - Suckling, Bruce N.
AU - Safta, Anca M.
AU - Long, David L.
AU - Waite, B. Moseley
AU - Morris, Peter E.
AU - Hite, R. Duncan
PY - 2012/6
Y1 - 2012/6
N2 - INTRODUCTION: Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids. METHODS:: Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function. RESULTS:: BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates. CONCLUSIONS:: These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS. copyright
AB - INTRODUCTION: Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids. METHODS:: Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function. RESULTS:: BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates. CONCLUSIONS:: These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS. copyright
KW - Acute lung injury
KW - Adult respiratory distress syndrome
KW - Phosphatidylglycerol
KW - Pulmonary surfactant
KW - Secretory phospholipase A2
UR - http://www.scopus.com/inward/record.url?scp=84862882764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862882764&partnerID=8YFLogxK
U2 - 10.1097/MAJ.0b013e318239c96c
DO - 10.1097/MAJ.0b013e318239c96c
M3 - Article
C2 - 22173044
AN - SCOPUS:84862882764
SN - 0002-9629
VL - 343
SP - 446
EP - 451
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 6
ER -